Overview of novel strategies for the delivery of anthracyclines to cancer cells by liposomal and polymeric nanoformulations
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články, přehledy
PubMed
32763404
DOI
10.1016/j.ijbiomac.2020.07.274
PII: S0141-8130(20)34038-1
Knihovny.cz E-zdroje
- Klíčová slova
- Anthracyclines, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Liposomes, Polymeric nanoformulations,
- MeSH
- antracykliny aplikace a dávkování MeSH
- farmaceutická chemie metody MeSH
- lidé MeSH
- liposomy chemie MeSH
- nádory farmakoterapie MeSH
- nanočástice chemie MeSH
- polymery chemie MeSH
- protinádorové látky aplikace a dávkování chemie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- antracykliny MeSH
- liposomy MeSH
- polymery MeSH
- protinádorové látky MeSH
Severe side effects and the rapid emergence of drug resistance in cancer cells are major problems in the chemotherapy utilizing anthracyclines, with a difference between cellular response at nano and micro scale levels. Understanding this situation is more complicated issue to attain efficient targeted formulations with low unexpected toxicity in patients. On nano-scale level, considering properties of nano-bio interaction in all relevant parts of the body may offer clue for suitable formulations. Four main strategies comprising PEGylation, surface charging, targeting, and stimuli responsiveness can be deployed to improve the liposomal and polymeric nanoformulations that can efficiently deliver common anthracyclines namely daunorubicin (DAU), doxorubicin (DOX), idarubicin (IDA), and epirubicin (EPI). Herein, the advances and challenges pertaining to the formulations of these anticancer drugs via liposomal and polymeric nanoformulations, are discussed.
Citace poskytuje Crossref.org
